Phase 2 study of Bevacizumab Beyond Progression treatment in patients with advanced non-squamous non-small-cell Lung cancer

Phase 2 study of Bevacizumab Beyond Progression treatment in patients with advanced non-squamous non-small-cell Lung cancer - BBPL study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007854

Enrollment

Registered

2012-04-30

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced non-squamous non-small-cell Lung cancer

Interventions

Patients received cisplatin 75 mg/m2 or carboplatin AUC 5 and pemetrexed 500 mg/m2, bevacizumab 15 mg/kg on day1 at 21-day intervals for 4-6 cycles.Patients who respond induction thepary move into mai

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)non small cell carcinoma and non squamous cell carcinoma (2)stage3B/4 or postoperative recurrence (3)no pretreatment patients (4)PS(ECOG)0-1 (5)patients have measurable lesion based on RECIST(ver1.1) (6)standard laboratory tests (7)patients don't have recent major surgery, radiation therapy, and so on (8)patients agreed this clinical study

Exclusion criteria

Exclusion criteria: (1)symptoms due to brain metastasis (2)hemoptysis (3)significant hemosputum (4)radiation therapy to chest region (5)significant infectious disease (6)severe conplication (7)uncontrollable acsites, plueral effusion, cardiac effusion (8)active multiple cancer (9)severe drug allergy (10)unnable to administer vitamin B12.reject to Vitamin B12 (11)interstitial pneumoniae or pulmonary fibrosis (12)uncontrollable hypertension (13)uncontrollable gastrointestinal tract ulcer (14)perforation of the digestive tract or experimental operation (15)doctors estimated innadequated

Design outcomes

Primary

Measure	Time frame
PFS of secondary treatment	—

Countries

Japan

Contacts

Public ContactKatsuhiko Naoki

Keio University Hospital Cancer Center

03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026